Biogen Inc
NAS : BIIB$232.65+1.76%Oct 16 close
Financials
Consolidated Balance Sheets
USD · reported units. Click a value to inspect its source.
| Reported line item | Dec 31, 2025 (current) | Dec 31, 2024 |
|---|---|---|
| Cash and cash equivalents | ||
| Current portion of marketable securities | ||
| Accounts receivable, net of allowance for doubtful accounts of $3.0 and $2.2, respectively | ||
| Due from anti-CD20 therapeutic programs | ||
| Inventory | ||
| Other current assets | ||
| Total current assets | ||
| Marketable securities | ||
| Property, plant and equipment, net | ||
| Operating lease assets | ||
| Intangible assets, net | ||
| Goodwill | ||
| Deferred tax asset | ||
| Investments and other assets | ||
| Total assets | ||
| Current portion of notes payable | ||
| Taxes payable | ||
| Accounts payable | ||
| Accrued expense and other | ||
| Total current liabilities | ||
| Notes payable | ||
| Deferred tax liability | ||
| Long-term operating lease liabilities | ||
| Other long-term liabilities | ||
| Total liabilities | ||
| Commitments, contingencies and guarantees (Notes 22 and 23) | — | — |
| Preferred stock, par value $0.001 per share | ||
| Common stock, par value $0.0005 per share | ||
| Additional paid-in capital | ||
| Accumulated other comprehensive income (loss) | ||
| Retained earnings | ||
| Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively | ||
| Total equity | ||
| Total liabilities and equity |
34 line items · 2 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.
Arithmetic validation is incomplete for this statement. Source values remain individually inspectable.